Published by Josh White on 8th December 2025
(Sharecast News) - Hutchmed China said on Monday that several of its oncology medicines would remain covered under China's state reimbursement system next year, while another had been added to a new commercial insurance list, expanding patient access and reinforcing the company's position in the country's multi-layered healthcare market.